Regeneron Pharmaceuticals’ (REGN) Outperform Rating Reiterated at Royal Bank of Canada

Royal Bank of Canada restated their outperform rating on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) in a research note issued to investors on Monday morning, Benzinga reports. The firm currently has a $1,229.00 price target on the biopharmaceutical company’s stock.

Several other research analysts have also weighed in on the stock. Evercore ISI assumed coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, May 14th. They set an outperform rating and a $1,150.00 price objective on the stock. UBS Group upped their price objective on shares of Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the company a buy rating in a research report on Wednesday, April 17th. Truist Financial reiterated a buy rating and set a $1,135.00 target price on shares of Regeneron Pharmaceuticals in a report on Wednesday, April 3rd. Morgan Stanley increased their price target on Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the stock an overweight rating in a report on Wednesday, March 13th. Finally, TD Cowen lifted their price objective on Regeneron Pharmaceuticals from $1,020.00 to $1,030.00 and gave the company a buy rating in a report on Wednesday, April 24th. One analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of Moderate Buy and a consensus target price of $1,008.96.

Regeneron Pharmaceuticals Price Performance

REGN opened at $1,069.16 on Monday. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.27 and a quick ratio of 4.51. The company’s 50 day simple moving average is $974.69 and its 200-day simple moving average is $947.43. Regeneron Pharmaceuticals has a one year low of $684.80 and a one year high of $1,081.17. The stock has a market capitalization of $117.81 billion, a P/E ratio of 31.59, a price-to-earnings-growth ratio of 2.21 and a beta of 0.13.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported $7.97 earnings per share for the quarter, missing analysts’ consensus estimates of $8.46 by ($0.49). Regeneron Pharmaceuticals had a return on equity of 16.83% and a net margin of 29.45%. The business had revenue of $3.15 billion for the quarter, compared to the consensus estimate of $3.19 billion. Sell-side analysts anticipate that Regeneron Pharmaceuticals will post 37.23 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Leonard S. Schleifer sold 25,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 14th. The stock was sold at an average price of $979.25, for a total transaction of $24,481,250.00. Following the transaction, the chief executive officer now directly owns 408,200 shares of the company’s stock, valued at approximately $399,729,850. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, CEO Leonard S. Schleifer sold 25,000 shares of the company’s stock in a transaction dated Tuesday, May 14th. The shares were sold at an average price of $979.25, for a total value of $24,481,250.00. Following the transaction, the chief executive officer now owns 408,200 shares in the company, valued at approximately $399,729,850. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Michael S. Brown sold 1,172 shares of the firm’s stock in a transaction that occurred on Tuesday, May 28th. The stock was sold at an average price of $974.86, for a total transaction of $1,142,535.92. Following the sale, the director now owns 1,382 shares of the company’s stock, valued at $1,347,256.52. The disclosure for this sale can be found here. Insiders have sold a total of 61,971 shares of company stock valued at $61,217,654 over the last 90 days. 7.48% of the stock is currently owned by insiders.

Institutional Trading of Regeneron Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in REGN. Envestnet Portfolio Solutions Inc. bought a new position in Regeneron Pharmaceuticals during the third quarter worth about $673,000. LPL Financial LLC raised its position in shares of Regeneron Pharmaceuticals by 9.3% in the third quarter. LPL Financial LLC now owns 40,733 shares of the biopharmaceutical company’s stock valued at $33,522,000 after buying an additional 3,479 shares in the last quarter. Mariner LLC boosted its stake in shares of Regeneron Pharmaceuticals by 2.9% in the third quarter. Mariner LLC now owns 7,518 shares of the biopharmaceutical company’s stock valued at $6,187,000 after buying an additional 214 shares during the period. Stifel Financial Corp grew its position in Regeneron Pharmaceuticals by 12.2% during the third quarter. Stifel Financial Corp now owns 31,030 shares of the biopharmaceutical company’s stock worth $25,537,000 after buying an additional 3,385 shares in the last quarter. Finally, Federated Hermes Inc. increased its stake in Regeneron Pharmaceuticals by 6.1% during the 3rd quarter. Federated Hermes Inc. now owns 2,796 shares of the biopharmaceutical company’s stock worth $2,301,000 after acquiring an additional 160 shares during the period. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.